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NEUROTROPHIN RECEPTORS IN SELECT CUTANEOUS MALIGNANCIES 
WITH A PROPENSITY FOR PERINEURAL INVASION 
NOAH S. FRYDENLUND 
ABSTRACT 
 Perineural invasion (PNI) in cutaneous squamous cell carcinoma (cSCC) and 
desmoplastic melanoma (DM) may be a negative prognostic finding, and likely 
contributes to increased rates of local recurrence. The biological mechanisms underlying 
PNI remain unclear, although several lines of evidence implicate neurotrophins and their 
receptors. Expression of the high affinity nerve growth factor (NGF) receptor TrkA has 
been shown to be associated with PNI in numerous malignancies, although literature in 
cutaneous neoplasms is sparse. Given this, we sought to ascertain the incidence of PNI in 
a cohort cSCCs using double immunostaining (DIS), and to investigate PNI’s relationship 
with TrkA expression and established histopathologic prognosticators. In DMs we 
investigated the relationship between TrkA and PNI. In DM we additionally analyzed 
expression of the low affinity NGF receptor (p75NGFR) and the presence of a functional 
polymorphism in the glial cell line-derived neurotrophic factor (GDNF) receptor RET 
(RETp) as they relate to PNI.  
 In this IRB approved study, cSCCs from the head and neck (H&N) and 53 from 
non-H&N areas were immunohistochemically analyzed for PNI (DIS with S100 and p63) 
and TrkA expression. For DM, 43 cases were immunohistochemically evaluated for 
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TrkA and p75NGFR expression while RETp was detected by direct DNA sequencing. 
The presence of each was correlated with histologically observed PNI.  
 In cSCCs, comparing H&N versus non-H&N areas;  using hemotoxylin and eosin 
(H&E) PNI was detected in 11% versus 6% of cases respectively and using DIS, in 23%  
versus 15% respectively, with significant disagreement between both methods (κ=0.47, 
p=0.002).  There was a 2.33 fold increase in PNI detection with DIS compared to H&E 
(95%CI: 1.12–4.87; p=0.02). TrkA expression was 2.9 times more frequently observed in 
cSCCs from the H&N compared to those from non-H&N areas (p=0.01). Regardless of 
site, TrkA expression was associated with decreased degree of differentiation (OR=6.46, 
p=0.0006) and high-risk morphologic variants (OR = 6.53, p=0.002). TrkA expression 
was not significantly associated with PNI (p=0.33). 
 In DM, PNI was present in 67% of cases. On univariate analysis; p75NGFR was 
associated with PNI (expression detected in 79% of PNI-positive cases compared to 36% 
of PNI-negative cases, p=0.005), increased Breslow’s depth and greater Clark’s Level 
(p= 0.007 and p= 0.01 respectively). RETp was noted in 28% of cases but was not 
significantly associated with PNI (p=0.27) or other histopathologic variables. TrkA 
expression was absent in all cases. PNI was associated with increased Breslow’s depth 
and Clark’s Level (p=0.01 and p=0.009 respectively). Controlling for the association 
between p75NGFR and depth, p75NGFR remained associated with an increased 
propensity for PNI (OR=4.68, p=0.04).  
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 In conclusion, increased PNI detection with DIS in cSCCs underscores the 
adjunctive utility of immunohistochemistry in microstaging. Although unlikely to play a 
role in the development of PNI, TrkA’s association with cSCCs from H&N and select 
histopathologic parameters suggests a role for the NGF-TrKA axis in tumorogenesis 
while its absent expression in DM suggests that expression is lineage-related. Lastly, In 
DM, p75NGFR expression is significantly associated with PNI and a more locally 
aggressive phenotype. 
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INTRODUCTION 
1.1 Perineural invasion in cancer  
Perineural invasion (PNI) refers to infiltration of the perineural sheath by tumor 
cells with subsequent tumor proliferation and spread, either proximally or distally along 
the length of the nerve.1 Best studied in carcinomas of the pancreas and prostate, PNI has 
long been understood be an important route of tumor spread.2 However PNI has been 
reported in a multitude of lineage-unrelated malignancies. The first recorded observation 
of PNI in a cutaneous malignancy was reported by Neumann in 1862.3 Since then, PNI 
has been reported in multiple cutaneous malignancies including desmoplastic melanoma 
(DM), basal cell carcinoma, microcystic adnexal carcinoma and cuteanous squamous cell 
carcinoma (cSCC).1,4–6 Of these, PNI is best studied in cSCC and DM both of which are 
known to have a marked propensity for this invasive feature.  
1.2 A note on definitions 
 While the definition of PNI as tumor cells present within the perineural sheath 
appears straightforward at first glance, in practice there are inconsistencies in the 
reporting of PNI.  In cSCC, the main point of contention centers on differentiating 
between true PNI and focal abutment of tumor on nerve (when the nerve is surrounded by 
tumor but not invaded).7  While originally defined in SCC by Batsakis et al. in 1985 as 
“Tumor cell invasion in, around and through the nerves”,8 which would include focal 
abutment, recent definitions have become more stringent. In her 2009 review, Liebig 
suggested that PNI should be defined as “finding tumor cells within any of the 3 layers of 
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the nerve sheath or at least 33% of the circumferences of the nerve surrounded by tumor 
cells”.2 Even more stringently, some authors propose that only observing tumor cells 
within the perineural sheath should be classified as PNI.9 and for our purposes we have 
chosen to use this definition when reporting PNI in our cases. 
 In melanoma a wholly separate problem presents itself when defining PNI. 
Namely, the conflation of the terms “Neurotropism or Neurotropic” with PNI. The term 
neurotropism was initially used by Reed and Leonard in 1979 to describe a subset of 
DMs that displayed prominent “Schwannian differentiation” and/or extensive PNI, which 
they termed neurotropic melanoma (NM).10 However, it should be noted that 
“neurotropic melanoma” may be used to describe any melanomas that exhibit the 
aforementioned characteristics, and there are reports of both epithelioid and spindle cell 
melanoma (SCM) without desmoplasia being classified as NM.9,11As a result, the label of 
desmoplastic neurotropic melanoma (DNM) has been used in the case of DMs that 
present with Schwannian differentiation and/or PNI  while NM is reserved for those cases 
without desmoplasia.  Further, because neurotropism can be used to describe both PNI 
and the distinct cytomorphologic feature of Schwannian differentiation (defined as 
melanoma cells taking on the cytology of nerve), confusion may result when attempting 
to determine its prognostic significance.11,12  
In an effort to reduce the equivocality of the nomenclature, we suggest the use of 
the term PNI as opposed to neurotropism when describing the histopathological 
observation invasion of peripheral nerve by melanoma cells. This usage is consistent with 
the terminology employed in describing other cutaneous malignancies.1 Hence, 
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melanomas that display PNI are termed NM, and more specifically DMs that display the 
same are termed DNMs (Figure 1). In the rare instances where PNI is not present but the 
melanoma displays a clear neural cytomorphology we agree with the recent suggestions 
of Su et al. in their case report of such a lesion, that these tumors should be classified as 
distinct from NM/DNMs, the authors suggested the use of the term “malignant 
neurotization”.12 Alternatively, the term neural transformation has been used to describe 
such lesions as well.13 The importance of properly distinguishing between NM and DNM 
so-named for prominent PNI vs. those named for neural transformation is more than just 
semantic. Neurotropism as PNI is likely to have a different prognostic implication than 
neurotropism as neural transformation, and at least one study has demonstrated this.13 A 
clearer understanding of the prognostic relevance of neurotropism would result from 
separating PNI from neural transformation in diagnosing NM and DNM. 
Figure 1.  Classification of neurotropic, and desmoplastic neurotropic melanoma.  
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1.3 Incidence of PNI in cutaneous malignancies 
 The incidence of PNI varies substantially across cutaneous malignancies. Within 
a given malignancy there may be further variations in incidence, dependent on 
histopatholiogic subtype. As a result, reported rates of PNI in the literature span a broad 
range. In cSCC the reported incidence of PNI varies substantially, with a range of 2-14%,  
though most studies report rates between 2% and 5%.4,14,15 Furthermore, It has been 
suggested that rates of PNI are higher in cSCCs of the head and neck (H&N) compared to 
other anatomic sites which may confound reports past reports.16 Comparisons of PNI 
incidence are complicated by multiple factors, that include the challenges associated with 
detection of PNI using H&E staining (obscured nerve and morphologically imperceptible 
tumor cells), lack of a standardized histological definition of PNI (delineating true PNI 
from focal abutment secondary to impingement of nerve by tumor), differences in 
detection rates between cryostat and formalin-fixed paraffin embedded tissue sections  
(Mohs micrographic surgery versus  traditional histopathologic examination)  and 
histological mimics such as Renault bodies, perineural fibrosis, reactive  neuroepithelial 
aggregates and reparative perineural hyperplasia. 7,15,17–21 Lastly, in select cutaneous and 
non-cutaneous malignancies it has been shown that the use of immunohistochemistry 
(IHC) can aid in the detection of PNI, especially in the tumor bulk where nerve can be 
obscured by tumor (intratumoral PNI).9,17,18,22 Such observations indicate that the true 
incidence of PNI in cSCC may be greater than what has been reported using H&E alone.  
 The reported incidence of PNI in melanoma varies substantially across studies. 
While it is well understood that the greatest rates of PNI are seen in the DM variant, the 
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conflation of PNI with neural transformation in the reporting of both NM and DNM 
makes it difficult to get a precise figure. In their 1998 study in 280 cases of desmoplastic 
melanoma, Quinn et al.  identified 30% of cases as the DNM variant.23 Although, what 
proportion of cases were diagnosed as DNM for PNI as compared to exclusively neural 
transformation was not specified.  Busam et al. reported that of 98 cases of DM,  53% 
displayed nerve involvement.5  The highest reported rate of 82%, occurred in a study of 
28 DMs of the head and neck, suggesting that anatomic location may be of relevance in 
determining incidence.24  There may be further variation in incidence within DM 
subtypes (pure vs mixed), with one study reporting that rates of neurotropism varied 
significantly, with a higher incidence in the pure subtype (43.9%) vs the mixed subtype 
(27.1%).25  The incidence of PNI in non-desmoplastic melanoma is substantially less.  
Scanlon et al. report that a query of 1,984 primary melanoma cases from the 
Interdisciplinary Melanoma Cooperative Group at NYU found an overall incidence of 
3%.9 However, this would include melanomas of all subtypes (both DMs and non-DMs). 
It was noted that cases of DM and acral lentiginous melanoma (ALM) were 
overrepresented in the PNI positive group.   
 
1.4  Prognostic Impact of PNI in cSCC and DM 
The prognostic relevance of PNI in both cSCC and melanoma remains equivocal. 
In most malignancies in which it is observed (both cutaneous and non-cutaneous) PNI is 
associated with a more aggressive phenotype, and increased risk of recurrence.2 In select 
  
6 
 
malignancies (pancreatic and prostate carcinomas) PNI may be associated with increased 
mortality.26,27 
In cutaneous malignancies, the prognostic impact of PNI has best been studied in 
cutaneous squamous cell carcinoma (cSCC). In 2010, based on a confluence of evidence 
from numerous prospective cohort studies, the American Joint Committee on Cancer 
(AJCC) added PNI as a high-risk tumor characteristic in tumor staging.28 The rationale 
for inclusion was drawn from Geopfert et al.’s findings in a retrospective review of 967 
cSCCs that PNI was linked to metastasis and reduced survival,14 as well as a study from 
Leibovitch et al. of 1,177 cSCCs demonstrating an association with recurrence, decreased 
degree of differentiation, and larger tumor diameter.4 Further support for the AJCC’s use 
of PNI in tumor staging comes from Cherpelis et al.’s investigation of 200  cSCCs  in 
which a correlation with metastasis was found,29 Clayman et al.’s analysis of 277 cases 
linking PNI to decreased disease-specific survival30 and Moore et al.’s finding in 193 
patients with cSCC of the H&N area that PNI is associated with lymph node 
metastases.31  The above, combined with the prevalence of cSCC as the second most 
common cutaneous malignancy underscore the clinical relevance of PNI identification.32  
Recently, subtleties that have emerged from investing PNI’s utility as a 
prognosticator in cSCC.  Namely, the importance of nerve diameter and presence of 
multiple foci of nerve involvement in determining outcomes of patients with PNI in 
cSCC.33  At least two studies have reported that in cSCC, PNI in nerves with a diameter 
>0.1mm is associated with worse outcomes (metastasis and recurrence) while 
involvement of nerves <0.1mm was not associated with negative outcomes.33,34  
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However, Lin et al. report that the diameter of the involved nerve had no impact on 
outcomes in cSCC.35 Additionally, Carter et al.  also report that the involvement of 
multiple nerves is associated with risk factors that portend worse outcomes when 
compared to solitary foci of PNI.34 While, Lin et al. similarly found that patients with 
focal PNI had better outcomes than those who had diffuse PNI with multiple foci of 
invasion.35 
A definitive understanding of PNI’s prognostic relevance in melanoma remains to 
be established. As mentioned previously, discordant definitions of neurotropism serve as 
a barrier to developing a comprehensive understanding of PNI as a potential prognostic 
indicator in its own right.  Initially neurotropism was understood to be a negative 
prognostic finding, with Baer et al. finding a significant decrease in 8 year overall 
survival when comparing both NM and DNM to their non-neurotropic counterparts.11 
Soon after, in the largest study to date (280 cases), neurotropism was correlated with a 
two fold increase in local recurrences but was not associated with survival.23  In both of 
these studies, the potential for “skip lesions” in which the tumor extension along the 
nerves results in falsely negative margins in biopsies was hypothesized to be the cause for 
the increase in local recurrence. Since then, the majority of studies have reported that 
neurotropism is not of significant prognostic relevance.36,37,24,25 (summarized in 
chronologic order in Table 1), although recently Scanlon et al. reported that PNI is 
associated with increased rates of local recurrence in both DM and non-DM cases.9  
Future studies that attempt to determine the prognostic relevance of PNI would benefit  
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greatly by laying out an explicit definition of neurotropism as PNI. Additionally, To our 
knowledge, the prognostic effects of nerve diameter and multiple foci of nerve 
involvement have not been investigated in melanoma. Future research into these variables 
would significantly enhance our understanding of the role PNI plays in affecting 
outcomes. 
 While the prognostic value of PNI remains equivocal, special care should be 
taken with cases of DNM/NM from the head and neck as anatomic location may 
significantly impact the prognostic influence of PNI. The involvement of cranial nerves 
may result in significant malignant neuropathies,13 and potentially increase the risk of 
metastasis to the central nervous system.16  In melanomas, perineural spread has been 
observed to occur beyond the skull base as far as the brain.16 
 
Table 1. Chronologic overview of studies reporting prognostic impact of 
neurotropism in melanoma 
Author/ Year Samples 
Studies (n) 
Findings Conclusion 
Smithers et al. 
1992 
DM (58) Visceral recurrence in tumors 
with neurotropism was less 
frequent than in those neural 
transformation.  
 
Local recurrence rate 
appeared to be higher in 
tumors with neural 
transformation than in tumors 
displaying neurotropism.  
 
Neural transformation 
is more predictive on 
local recurrence than 
neurotropism.13 
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Baer et al. 
1995 
NM      (5) 
DNM  (11) 
The 8 year survival rate was 
90% in patients without 
neurotropism and 60% in 
those with neurotropism.  
 
Local recurrence occurred in 
36% of DNMs and 20% of 
NMs.  
Neurotropism is a 
negative prognostic 
indicator.11 
Quinn et al. 
1998 
DM     
(190) 
DNM   
(90)  
Local recurrence occurred in 
45% of DNMs compared to 
21% of DMs.  
 
There was no difference in 
survival between DM and 
DNM patients. 
Neurotropism portends 
local recurrence, but 
not decreased survival 
in DM.23 
Su et al. 
2003 
DNM  (14) 
DM     (19) 
There was no significant 
association between sentinel 
lymph node metastasis and 
neurotropism. 
 
 
Neurotropism does not 
increase the risk for 
lymph node metastasis 
in DM.36 
Busam et al. 
2004 
DM     (92) 
 
Neurotropism was not 
significantly associated with 
reduced disease free survival 
(p=0.21).   
Neurotropism was only 
marginally associated 
with reduced Disease-
Free survival.5 
Kay et al. 
2004 
DNM  (23) 
DM      (5) 
Neurotropism was not 
significantly associated with 
overall survival, local 
recurrence, or distant 
metastasis.  
Neurotropism is not of 
prognostic relevance in 
DM.24 
Livestro et al.  
2005 
DM (39) 
DNM (50) 
Neurotropism was not 
significantly associated with 
survival or local recurrence.  
 
Of cases with lymph node 
metastasis 75% were 
neurotropic.  
Neurotropism is not of 
prognostic relevance in 
DM.38 
Chen et al. 
2008 
DNM  
(128)  
Local recurrence occurred in 
6% of DNM cases.  
Neurotropism may not 
predict local recurrence 
to the extent previously 
thought.37 
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Murali et al. 
2010 
DM     
(163) 
DNM  (89) 
Neurotropism was not 
associated with local regional 
recurrence.  
Neurotropism is not a 
prognostic indicator of 
increased risk for local 
regional recurrence.25 
Scanlon et al. 
2014 
DNM   
(19) 
NM      
(23) 
 
PNI detected associated with 
local recurrence. 
 
PNI detected by H&E was 
associated reduced rates of 
ulceration. 
Neurotropism portends 
local recurrence but not 
decreased survival in 
multiple melanoma 
variants.9 
 
 
1.5  The biological underpinnings of PNI – the role of neurotrophins.  
A comprehensive understanding of the biological processes that promote PNI has 
yet to be established in any malignancy with a propensity for PNI.  Two potential 
frameworks to explain the pathogenesis of PNI have been proposed. In one, tumor cells 
adopt a phenotype that enables them to respond to the distinctive microenvironment of 
nerves and thus acquire properties of enhanced invasiveness and proliferation. In the 
other, tumors themselves may develop a microenvironment that promotes neurite 
outgrowth, resulting in the proliferation of nerve twigs into and around the tumor with 
resulting PNI.  These two mechanisms are not mutually exclusive and it is likely that 
some level of both occur at the same time through reciprocal signaling between tumor 
cells and nerve.2  
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To date, attempts to illuminate the molecular players involved in the pathogenesis 
of PNI have focused primarily on a family of peptides known as 11eurotrophins and their 
respective receptors.  Neurotrophins are principally known for their role in controlling the 
development and maintenance of the peripheral nervous system but are increasingly 
understood to play significant roles in behavior of multiple  lineage-unrelated cancers.2  
The most well characterized neurotrophin is nerve growth factor (NGF), but there are 
several other members of the neurotrophin family including brain-drived neurotrophic 
factor (BDNF), neurotrophin 3 (NT-3) and neurotrophin 4/5  (NT-4/5).37,38 Glial cell 
line-derived neurotrophic factor (GDNF) has a similar functional role to the 
aforementioned 11eurotrophins and is often grouped together with the NGF-related 
neutrophins. However, structural differences between GDNF and the NGF family warrant 
that it be considered in its own separate class of 11eurotrophins ( the GDNF family of 
neurotrophic factors).39 There are several receptors that interact with varying degrees of 
specificity with 11eurotrophins. The most studied are the Trk family of receptors ( which 
includes TrkA, TrkB, and TrkC), p75NGFR, and RET. The Trk family and RET are 
comprised of receptor tyrosine kinases, while p75NGFR is a member of the tumor 
necrosis factor receptor superfamily.40,41 The Trk family and RET are known to bind their 
target 11eurotrophins with relatively high-affinity and selectivity (TrkA binds NGF and 
NT-3, TrkB binds BDNF, NT-3, and NT 4/5, TrkC binds NT-3, RET binds GDNF) while 
p75NGFR is more promiscuous, binding a multitude of 11eurotrophins with different 
affinities.  Within the context of PNI in cutaneous malignancies, the TrkA-NGF axis, 
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RET, and p75NGFR have emerged as the most promising neutrophin/nuerotrophin 
receptor candidates for having a mechanistic role.  
 
1.5.1 The NGF-TrkA axis and PNI 
 TrkA serves as the membrane-bound high-affinity receptor for NGF and is 
expressed in multitude of lineage-unrelated cells.  In normal epidermis, TrkA expression 
is found to be greatest in basal keratinocytes with expression dissipating in the superficial 
layers of the epidermis.  There are conflicting reports of TrkA expression in normal 
melanocytes.42,43 In epidermal keratinocytes as well as keratinocytes of the follicular 
epithelia, TrkA is thought to responsible for mediating NGF-induced stimulation of 
proliferation and inhibition of apoptosis.43–46 The pro-proliferative effects of NGF on 
cells expressing TrkA combined with the NGF rich microenvironment surrounding 
nerves as a result its secretion by Schwann cells,47 has led many to hypothesize a 
connection between TrkA and PNI.    
Studies in several non-cutaneous malignancies have shown TrkA expression to be 
associated with PNI.48–53 In both salivary adenoid cystic carcinoma and pancreatic ductal 
adenocarcinoma, TrkA was found to mediate enhanced invasiveness in cell cultures in 
response to NGF treatment.50,53 In pancreatic cancer cell lines this pro-invasive response 
has been linked to an increased production of select matrix metalloproteinases (MMP-2) 
in response to NGF.54 It is hypothesized that the expression of TrkA receptors on tumor 
cells allows them to responds to the NGF- rich microenvironment surrounding nerves, 
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resulting in increased production of proteolytic and enzymes and subsequent invasion 
through the perineural sheath.  In cutaneous malignancies, evidence for TrkA’s 
association with PNI was first reported in a study by Chen-Tsai et al. in which 4 cases of 
squamous cell carcinoma with PNI and 3 cases without PNI were analyzed 
immunhistochemically for Trk expression.6 Notably, the authors used a promiscuous 
antibody that binds TrkA, B, and C. The authors found staining was strongest in the PNI 
positive cases suggestive of a relationship between TrkA and PNI but limited sample size 
and non-specificity of the antibody prevented any conclusive conclusions from being 
made.  
Evidence for TrkA expression in melanomas is conflicting. Data from in vitro 
studies has shown TrkA expression to be absent.55–57 While an immunohistochemical 
study in 152 primary and 64 metastatic melanoma biopsies detected significant levels of 
expression of the activated form of the TrkA receptor (p-TrkA), with expression being 
observed more frequently in  biopsies of primary tumors (55%) compared to metastases 
(30%).58 In the same study, the authors reported that membranous p-TrkA expression was 
significantly associated with decreased overall survival, and elevated markers of 
proliferation (cyclin-A and Ki-67). Although, p-TrkA expression was seen more often in 
nodular melanomas than the superficial spreading variant, spindle cell and desmoplastic 
melanomas were not included in the study.  
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1.5.2 The GDNF-RET axis and PNI 
RET is a pro-oncogene encoding a membrane-bound receptor tyrosine kinase for 
GDNF. RET acts in concert with the GFRα1  co-receptor to bind GDNF, and like NGF-
TrkA signaling, the RET-GDNF axis serves to support the survival and development of 
the peripheral nervous system.59 Activating mutations in the RET gene have been 
associated with numerous cancers including neuroblastoma, papillary thyroid carcinoma, 
pancreatic cancers, and colon cancer.59–61 Interestingly, inactivating mutations in RET 
have been associated with deficiencies in neural crest cell migration during development, 
most notably in Hirschsprung’s disease which is caused by insufficient development of 
the enteric nervous system.62  
Most of the research into RET’s role in malignancies  has been done in pancreatic 
cancers where  RET-GDNF signaling has emerged as an important mediator of PNI.63–65  
Using immunohistochemistry, Zeng et al. have shown strong positive staining for GDNF 
in 88% of pancreatic ductal adenocarcinomas with PNI compared to 60% of those 
without PNI.65  Furthermore, in vitro experiments have shown that treatment of 
pancreatic cancer cell lines with GDNF results in an increased production of matrix 
metalopreinase-9 (MMP-9) with a corresponding increase in invasive capacity – an effect 
that is lost after treatment with an inhibitor of RET.66 Secretion of proteolytic enzymes 
like MMP-9 may facilitate degradation of the perineural sheath, essential for PNI. Taken 
together, the pro-invasive effects of GDNF-RET signaling, combined with the increased 
expression of GDNF in PNI positive pancreatic cancers, lend credence to the hypothesis 
that RET-GDNF signaling plays a role in the development of PNI.  
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Adding another dimension to the RET-PNI connection, a study conducted by 
Cavel et al. showed nerves invaded by pancreatic cancer had significantly elevated 
populations of endoneurial macrophages in excisions from both patients and mice.63 
These macrophages were found to secrete high levels of GDNF which when applied  to 
pancreatic cells in culture promoted chemotactic migration of the cancer cells. 
Furthermore, the migration enhancing effect was lost after the pancreatic cancer cells 
were transfected with either siRNA against GFRα1 or RET inhibitor treatment, 
suggesting paracrine signaling between cancer cells expressing GFRα1/RET and GDNF 
secreting endoneurial macrophages. Most recently, it has been shown in a mouse model 
for PNI that peripheral nerves are capable of releasing soluble GFRα1 receptor, which 
enables GDNF binding in pancreatic cancer cells that lack GFRα1 but express RET, 
resulting in PNI.64 Conversely, in this same study it was shown that tumor cells that lack 
RET did not undergo PNI, even in the presence of soluble GFRα1.  Taken together, these 
results suggest that RET’s causative relationship with PNI may be dependent on both 
paracrine signaling involving endoneurial macrophages, and additionally requires the 
presence of the GFRα1 co-receptor either in it’s soluble form or expressed on the tumor 
cells themselves. 
 While the literature is lacking regarding the role of RET in cSCC, numerous lines 
of evidence suggest that RET is of importance in the pathogenesis of melanoma. 
Transgenic mouse lines with either over-activated RET mutations or overexpression of 
wild-type RET develop melanosis and benign melanocytic lesions that eventually 
progress to metastatic melanoma.67–71  It has been shown that the progression from 
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benign lesions to melanomas corresponds with increasing levels of RET expression and 
its activation in tumors from these mouse models.69 . It is also interesting to note that in 
RET transgenic mice, repeated UV irradiation results in the activation of RET leading to 
melanocytic tumor development at an accelerated rate compared to sham irradiated 
controls.70 Evidence from human melanoma cell cultures further underscores the 
potential role of RET-GDNF signaling in melanomagenisis.  In select human melanoma 
cell lines, Mrna transcripts for RET, GFRα1, and GDNF were detected, while human 
melanocytes were found to only express GFRα1.71  A functional polymorphism (G691S) 
in the RET gene (RETp) has been shown to amplify RET’s responsiveness to GDNF 
treatment in melanoma cell culture.72,73 This mutation is found as a germline mutation in 
15-20% of the general population but may also occur as somatic mutation in some 
instances.73 Compared to RETwt melanoma cells, those with RETp displayed amplified 
proliferation, migration, and invasion after the addition of GDNF to culture medium, 
suggesting that RETp sensitizes the RET receptor to GDNF stimulation.72 Furthermore, 
when Narita et al. analyzed 71 non-DM biopsies and 70 DM biopsies, the incidence of 
RETp was greater in the DM group than in the non-DM group (61% and 31% 
respectively).72  Our own experience indicates that within DM, RETp  is more frequently 
found in the pure subtype as compared to the mixed subtype.74 As DMs are found 
predominantly in chronically sun exposed areas, the known role of UV light in modifying 
RET signaling may be of importance.  Although RET-GDNF signaling appears to play a 
role in the development of PNI in pancreatic cancers, and additionally the activating 
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RETp mutation is found to be more frequently expressed in DM, a firm connection 
between RET and PNI in melanoma remains to be established.  
 
1.5.3 p75NGFR and PNI 
The most studied of all the neurotrophin receptors in melanoma, especially in the 
spindle cell and desmoplastic variants, is p75NGFR (alternatively called p75NTR, 
CD271, and the low affinity NGF receptor).  The p75NGFR receptor is also the most 
promiscuous of neurotrophin receptors and is known to bind NGF, NT-3, NT-4/5, and 
BDNF with somewhat lower affinity than the Trk family of neurotrophin receptors. 
Unlike the Trk family and RET, p75NGFR is not a receptor tyrosine kinase,  belonging 
instead to the tumor necrosis factor receptor superfamily.41 In neurons, the role of 
p75NGFR is complex and poorly understood. It has been suggested that in the presence 
of TrkA, p75NGFR acts to increase TrkA’s binding affinity for NGF and promote 
survival while, in the absence of TrkA, NGF binding to p75NGFR induces apoptosis.41 
Additionally, the migration of Schwann cells during embryonic development is thought 
to be regulated by p75NGFR.75 In cancers, strong expression of p75NGFR is often seen 
in schwanomas, neuroblastoma, and other tumors of neural crest origin, although it’s 
functional role is still unclear.76 
Conflicting reports exist regarding the expression of p75NGFR in melanocytes. 
Numerous in vitro studies have found expression of p75NGFR in human melanocyte cell 
culture.77 In addition, it has been shown that treatment of melanocyte cell cultures with 
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phorbol 12-tetradecanoate 13-acetate, a potent activator of protein kinase-C, induces 
upregulation of p75NGFR expression and causes the melanocytes to adopt a dendritic 
cytomorphology.77 However, ex vivo studies using immunohistochemistry have reported 
negative p75NGFR staining in melanocytes but positive staining in nevic corpuscles 
within neurotized nevi.78 Most immunohistochemical studies on formalin-fixed paraffin-
embedded tissue samples report negative p7NGFR staining in epidermal melanocytes. 
 In 1996, two studies reported that p75NGFR was strongly expressed in 
melanomas with a spindled phonotype, including DM and SCM, but not in epithelioid 
melanomas.79,80 Iwamoto et al. observed that p75NGFR was strongly expressed in all 
DMs and SCMs studied while only expressed in 1/11 (9%) of epithelioid melanomas.79  
At the same time, Kanik et al. emphasized the diagnostic utility of p75NGFR as an 
immunohistochemical adjunct for diagnosing DM in S100 negative spindle celled 
lesions, finding that p75NGFR had superior staining characteristics compared to S100 in 
both SCM, DM and NM.80  They also noted that p75NGFR staining had an inverse 
relationship with HMB-45 staining, as tumors that stained strongly for p75NGFR did not 
express HMB-45 and vice versa. Since these early reports from 1996, several studies 
have used p75NGFR immunohistochemical staining in an attempt to enhance diagnostic 
accuracy in spindle celled melanomas. Usually, p75NGR staining is compared to that of 
S100, a well-established marker of neural crest-derived cells. S100 is nearly ubiquitously 
expressed across all melanoma variants, however in rare instances S100 negative SCMs 
and DMs have been reported, presenting a diagnostic pitfall for the pathologist.81 In these 
instances p75NGFR has been shown to be a superior marker for melanoma, and, based on 
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this, many have recommended inclusion of p75NGFR in an initial immunohistochemical 
screening panel when dealing with equivocal cutaneous spindle celled lesions.80,82,83  
Although p75NGFR may indeed be useful in the identification of SCM and DM 
in S100 negative cutaneous spindle cell lesions, discrepancies in the literature regarding 
its sensitivity,84,85 as well as staining in scars,86,87 present potential diagnostic pitfalls. 
Immunohistochemical studies have shown variable expression of p75NGFR in SCM and 
DM, ranging from 17% 85 to 100%.71,79,82,83 The reasons for these discrepancies are not 
clear, and may be the result of a combination of factors.  Briefly, these may include 
variability in antibodies, concentrations, and epitope retrieval methods. Our own analysis 
of studies utilizing p75NGFR staining indicates no unifying reason for the discrepancy in 
results. Notably, the studies by Kanik et al. and Huttenbach et al. each used the same 
antibody (p75NGF-R from Boehringer, Manheim) with markedly different results (Kanik 
et al. reported 100% positivity in SCM/DM while Huttebach et al. reported 33%).80,84 A 
second source of variability may be a result of variable scoring rubrics used to establish 
criteria for p75NGFR positivity.  Our own experience underscores the need for 
establishing rigid, clear, and scientifically grounded cutoffs for positivity when 
attempting to correlate immunohistochemical staining with histopathological parameters. 
This is more complicated in the realm of DMs where it has been shown that in the mixed 
subtype, p75NGFR staining is mostly present in the spindle cell component but not in 
cells with epithelioid cytomorphology.82  
Iwamota et al. first hypothesized that p75NGFR may play a role in mediating PNI 
in melanomas after observing that p75NGFR was expressed in a significantly greater 
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proportion of DMs than epithelioid melanomas.79,88 The authors suggested that the 
expression of p75NGFR in melanoma cells may allow them to respond with increased 
invasiveness and proliferation to the NGF rich microenvironment surrounding nerves. It 
was known at the time that p75NGFR expressed in melanoma cell lines mediated NGF 
induced extracellular matrix invasion, most likely through increased production of 
heparanase (a protease capable of digesting key components of the extracellular 
matrix).56–58 Additionally, Iwomota et al. reported that p75NGFR mediated NGF’s 
survival promoting effects in melanoma cell cultures.88 Taken together, these 
observations supported Iwamoto et al.’s hypothesis.  However, since they did not report 
directly on rates of PNI, they could only conclude that p75NGFR was associated with the 
SCM and DM variants and not functionally involved in PNI.  The first study to attempt to 
directly correlate p75NGFR expression and PNI came from Chan and Tahan in 2009, in 
which the authors used immunohistochemistry to compare p75NGFR expression in a 
cohort of PNI positive vs. PNI negative melanomas of diverse histopathologic subtypes 
(DM, SCM, and epitheliod melanomas).85 They observed p75NGFR expression in 8/10 
PNI positive melanomas compared to 1/9 PNI negative melanomas, and that “all invasive 
melanomas with PNI showed some degree of spindle cell differentiation in the vertical 
growth phase”.85  
 Outside of its connection to PNI, additional perspectives on the role of p75NGFR 
in melanomagenisis have emerged in recent years. In 2010, Boiko et al. published a 
report of a subpopulation of “melanoma initiating cells” that to behaved as cancer stem 
cells.89 When transplanted into mice with engrafted human skin, these cells consistently 
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resulted in the development of melanoma tumors and in some cases metastasis to lungs 
and liver. Using fluorescence activated cell sorting in freshly resected melanomas, it was 
determined that CD271 (p75NGFR) was a reliable marker for these melanoma initiating 
cells. Notably, when taken from the same tumors CD271+ but not CD271- cells resulted 
in melanoma development after transplantation into mice. Of the resected tumors 
expressing CD271+, expression was found in between 2.5% and 41% (average of 16.7%) 
of the tumor cell population, and similar proportions were observed in the melanomas 
that developed in mice after transplantation of CD271+ cells. These results suggest that 
that CD271+ cells are capable of regenerating the more differentiated CD271- cells in 
vivo. The authors also report that CD271+ cells lack expression of traditional melanocyte 
(Tyrosinase/MART/HMB-45).  These finding were replicated by Civenni et al. with the 
additional finding that transplanted CD271- cells were at times capable of forming 
tumors but only in natural killer cell depleted and SCID mice.90  Interestingly, in the 
same study the authors report that staining a microarray of 200 primary and metastatic 
melanomas taken from patients showed that co-expression of CD271 and SOX10 was 
associated with metastasis and worse prognosis. The inverse correlation between 
p75NGFR expression and melanocyte markers in vitro was further elucidated in two 
recent studies.91,92 Furuta et al. observed that cytotoxic T-lymphocytes secrete NGF 
which, upon binding to p75NGFR on melanoma cells, results in the down-regulation of 
melanocyte markers.91 Additionally p75NGFR was found to be frequently co-expressed 
with programmed cell death ligand 1 (PDL-1), a potent inducer of cytotoxic T-
lymphocyte apoptosis and that both p75NGFR and PDL-1 may be upregulated in 
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response to interferon gamma. These results have important implications in explaining 
the frequent failures of targeted T-cell therapy towards traditional melanoma antigens. In 
the second study, Redmer et al. showed that knockdown of CD271 in melanoma cell lines 
results in a loss of other neural crest stem cell markers such as SOX10 and furthermore 
that expression of melanocyte markers and CD271 was mutually exclusive.92 Of potential 
relevance to DM, this change was associated with an alteration in cytomorphology from 
spindled to an epithelioid variant.  
 From a review of the literature, it appears that pathologists and basic scientists 
have distinct schools of thought regarding the role of p75NGFR.  Pathologists have been 
focused on employing staining for p75NGFR to improve diagnostic accuracy in spindle 
cell lesions as well as understanding its potential role in mediating PNI, while 
investigators seeking to understand the underlying fundamental biology of melanomas 
have focused on p75NGFRs role as a potential marker for melanoma stem cells. It is 
difficult to reconcile the observations that p75NGFR is associated with tumor initiating 
cells and suppression of T-lymphocytes while at the same time pathologists know it to be 
associated with DM which as discussed previously, has a relatively good prognosis. To 
reconcile these perspectives, significant gains in our understanding of the complex 
behavior of the p75NGFR receptor are required. The potentially varying effects of its 
numerous ligands, the consequences of its interactions with the Trk family of 
neurotrophin receptors, and its newly appreciated role as a marker for tumor initiating 
cells are all areas ripe for future investigation.  
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1.6Aims/Objectives 
Given the unresolved questions regarding the biological underpinnings of PNI, 
and it’s somewhat equivocal nature as a histopathologic prognosticator, we sought to 
further investigate PNI and the expression of select neurotrophin receptors in cSCC and 
DM.  
In the current study we sought to answer the following questions:  
 How does PNI correlate with established histopathologic prognosticators in cSCC 
and DM? 
 Does the use of p63/S100 double immunostaining (DIS) improve the detection of 
PNI in cSCC? 
 Does TrkA (in DM and cSCC), RETp (in DM), or p75NGFR (in DM ), correlate 
with propensity for PNI or other histopathologic prognosticators? 
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Cutaneous Squamous Cell Carcinoma – Materials and Methods 
2.1 Sample Selection 
This study was approved by the institutional review board of Boston University 
School of Medicine (IRB Docket #s H-32816, H-32952). Archival tissue samples with a 
diagnosis of cSCC from H&N (n=57) and non-H&N areas (n=53) were retrieved from 
the pathology files of the Skin Pathology Laboratory, Boston University School of 
Medicine, Boston, MA, USA. Inclusion criteria were randomly selected cases of primary 
cSCC with adequate tumoral tissue to allow for immunohistochemical analyses. 
Histologic sections of all cases were reviewed by two board-certified dermatopathologists 
(initial sign-out on all by a dermatopathologist; cases were then re-reviewed, and the 
diagnoses confirmed). All patient data were de-identified. 
2.2 Immunohistochemical analyses 
For all stains, formalin-fixed, paraffin-embedded tissue of primary cSCC (n=110)  
were baked at 75°C for 30 min. Sections were deparaffinized with xylene and rehydrated 
in a series of decreasing concentrations of ethanol solution. Heat-induced antigen 
retrieval was carried out in DAKO retrieval solution (DAKO, Carpenteria, CA, USA) 
with a Ph of 6.1 in a 98°C bath for 20 minutes. All immunostained slides were reviewed 
and scored in a blinded fashion. 
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2.2.1 Double staining for PNI detection 
Surface cuts from the same block (on which H&E staining was done) were double 
stained with p63 and S100 to evaluate PNI. Briefly, slides were treated with dual 
endogenous enzyme block (DAKO) then incubated with anti-p63 rabbit monoclonal 
antibody (BioCare, Concord, CA, USA) 1:100 dilution for 40 min at room temperature, 
followed by treatment with polymer HRP (DAKO) for 20 minutes. Color was developed 
with DAB (DAKO).  Slides were then incubated with Doublestain Block (DAKO) for 10 
minutes followed by a 40 minute incubation with anti-S100 rabbit monoclonal antibody 
at a dilution of 1:500. After treatment with the second antibody, slides were incubated 
with Rabbit/Mouse Link (DAKO) for 20 minutes, followed by polymer/AP (DAKO) for 
20 minutes. Color and contrast were developed with permanent red solution (DAKO) and 
hematoxylin respectively.  For p63, nuclear staining of epidermal basal and suprabasal 
cells, outer root sheath of hair follicles, and the germinitive layer of sebaceous glands 
served as positive internal controls in each case where they could be visualized. For 
S100, cytoplasmic staining of Langerhans cells, basal melanocytes, and uninvolved nerve 
fibers served as positive internal controls in each case where they could be visualized.   
Original H&E slides as well as DIS slides were reviewed in a blinded fashion for 
presence of PNI.  PNI positive status was assigned to samples in which the presence of 
neoplastic cells within the perineural space was observed. Only unequivocal cases of PNI 
were recorded as positive. 
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2.2.2 Assessment of TrkA expression 
The slides were treated with dual endogenous enzyme block (DAKO) then 
incubated with the anti-TrkA (14G6) rabbit monoclonal antibody (Cell Signaling 
Technology, Danvers, MA, USA) at a dilution of 1:200 for 50 minutes at room 
temperature, followed by treatment with polymer HRP (DAKO) for 20 minutes. Color 
development and contrast were achieved using DAB and hematoxylin respectively.   
 Given TrkA’s role as a membrane bound receptor tyrosine kinase, positive TrkA 
expression was defined as either membranous or mixed membranous/cytoplasmic 
staining observed in tumor cells. Tumor cells displaying only cytoplasmic staining were 
considered negative.  Membranous staining of basal epidermal cells, eccrine epithelial 
cells, mature sebocytes, and the outer root sheath of hair follicles served as positive 
internal controls where they could be visualized. A semi-quantitative scoring system was 
utilized with scoring cutoffs as follows: 0=0%, 1=1-5%, 2=6-25%, 3 = 26-50%, 4 = 
>50%.  For purposes of statistical analysis, cases with a score of 3 or higher were 
considered positive. 
 
2.3 Statistical Analysis 
A chi-square test of independence was used to examine differences in the 
distribution of demographic and prognostic variables between the following groups: 
H&N versus non-H&N; PNI-positive versus PNI-negative; and TrkA-positive versus 
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TrkA-negative cases. In ascertaining the association of PNI with histopathological 
variables, cSCC cases were pooled regardless of where expected frequency counts were 
less than 5, Fisher’s exact test was used to generate χ2 and p-values. DIS was compared 
to H&E using a Cohen’s Kappa coefficient of agreement. The association between TrkA 
and PNI staining was explored using Spearman’s Rank Correlation, and cases of cSCC 
were pooled regardless of their location (H&N or non-H&N). Stuarts’ Tau-C was utilized 
to verify statistical results from correlation of TrkA and PNI. All statistical tests were 
done using SAS® 9.3. 
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Cutaneous Squamous Cell Carcinoma – Results 
3.1 Comparison of histopathologic characteristics of cases from the H&N and non-
H&N areas  
 Of cases from the H&N, 42/57 (74%) were from males compared to 24/53 (45%) 
of non-H&N cases (p=0.002) and 42/57 (74%) of cases from the H&N were well 
differentiated compared to 48/53 (91%) of those from non-H&N areas (p=0.003, Table 
2). While cases from the H&N displayed on average a shallower depth of invasion and 
lower Clark Level than cases from non-H&N areas, differences  did not achieve statistical 
significance (p=0.28 and p=0.13 respectively).  High-risk morphologic variants 
(acantholytic/pesudoglandular, desmoplastic, or spindle cell subtypes) were more 
common in cases of the H&N than those from non-H&N areas (19% versus 9.4% 
respectively) although this difference was not significant (p=0.14). 
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Table 2. Histopathologic characteristics of cutaneous SCCs from the H&N and non-
H&N areas  
Variable 
H&N cases, No. (%) 
n=57 
Non-H&N cases, No. 
(%) n=53 
p-
values 
Sex 
   Male 
   Female 
 
42   (73.7) 
15   (26.3) 
 
24   (45.3) 
29   (54.7) 
 
0.002* 
Depth (mm) 
   0.01-2.00 
   2.01-3.99 
   > 4.00 
 
21   (36.9) 
30   (52.6) 
6     (10.5)  
 
12   (22.7) 
35   (66.0) 
6     (11.3) 
 
0.280 
Clark Level 
   I 
   II 
   III 
   IV 
   V 
 
0     (0.0) 
0      (0.0) 
13   (22.8) 
44   (77.2) 
0     (0.0) 
 
0    (0.0) 
0     (0.0) 
6    (11.3) 
47  (88.7) 
0    (0.0) 
 
0.130 
Differentiation 
   Well differentiated 
   Moderately 
differentiated  
   Poorly differentiated 
 
42   (73.7) 
15   (26.3) 
0     (0.0) 
 
48   (90.6) 
5     (9.4) 
0     (0.0) 
 
0.003* 
High-risk Morphologic 
Varianta 
   Yes 
   No  
 
11   (19.3) 
46   (80.7) 
 
5     (9.4) 
48   (90.6)  
 
0.140 
aHigh-risk morphologic variants include acantholytic, desmoplastic, or spindle cell 
subtypes 
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3.2 PNI in cSCC 
 
  Review of H&E stained sections, revealed PNI in 6/57 (11%) of cases from the 
H&N and 3/53 (6%) of cases from non-H&N areas (p=0.49).  Using DIS, PNI was 
detected in 13/57 (23%) of cases from the H&N and 8/53 (15%) of cases from non-H&N 
areas (p=0.30). Thirteen additional cases of PNI were detected with DIS (Fig. 2), 
representing an increase of 2.33 times compared to H&E (95%CI: 1.12–4.87; p=0.02). Of 
these, 7 involved nerves where located intratumorally while 6 involved nerves where 
located peritumorally (Fig. 3). In the H&N, DIS increased the rate of PNI pickup by 2.17 
times compared to H&E (13/57 versus 6/57; 95%CI: 0.89–5.30; p=0.08) while in non-
H&N areas, DIS increased the rate of PNI pickup by 2.67 times compared to H&E (3/53 
versus  8/53; p=0.20).  There was discordant detection of PNI determined by H&E 
compared to DIS (κ=0.47, p=0.002). Of histopathologic prognosticators evaluated, only 
tumor depth was found to be significantly associated with PNI (p=0.002) (Table 3). 
Furthermore, a linear trend was observed showing increasing depth correlates with 
increased incidence of PNI (p=0.008) 
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Table 3. PNI detected by double immunostaining and histopathologic 
prognosticators 
Variable 
PNI positive casesa 
No. (%) n = 21 
PNI negative casesa 
No. (%) n = 89 
p-
values 
Sex 
   Male 
   Female 
 
15    (71.4) 
6      (28.6) 
 
51    (57.3) 
38    (42.7)  
 
0.320 
Depth (mm) 
   0.01-2.00 
   2.01-3.99 
   > 4.00 
 
0      (4.8) 
16    (76.2) 
4      (19.0)  
 
32    (36.0) 
49    (55.0) 
8       (9.0) 
 
0.006* 
Clark Level 
   I 
   II 
   III 
   IV 
   V 
 
0      (0.0) 
0      (0.0) 
3      (14.3) 
18    (85.7) 
0      (0.0) 
 
0        (0.0) 
0        (0.0) 
16     (18.0) 
73     (82.0) 
0       (0.0) 
 
 
1.00b 
Differentiation 
   Well differentiated 
   Moderately differentiated  
   Poorly differentiated 
 
17   (80.9) 
4     (19.1) 
0     (0.0) 
 
73    (82.0) 
16    (18.0) 
0      (0.0_ 
 
1.00b 
High-risk Morphologic 
Variantc 
   Yes 
   No 
 
 
3    (14.3) 
18  (85.7) 
 
 
13    (14.6) 
76    (85.4)  
 
 
1.00b 
*Unadjusted p-values were calculated using chi-squared test of independence or Fisher’s test 
when expected frequencies were less than 5; unadjusted p-values were considered significant 
when <.05  
acases were pooled from H&N and non-H&N regions to examine bivariate associations with PNI.   
bThere was insufficient power to resolve an approximate p-value using Fisher method.  
cHigh Risk Variants include acantholytic, desmoplastic, or spindle cell subtypes.  
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Figure 2. Bar chart demonstrating PNI incidence by H&E and double 
immunostaining 
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Figure 3. Representative examples of double immunostaining with p63 (for tumor, 
nuclear staining, brown chromogen) and S100 (for nerve, cytoplasmic staining, red 
chromogen) 
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3.3 TrkA in cSCC 
  TrkA expression was 2.90 times more likely to be observed in cases from the 
H&N compared to non-H&N areas (28/57 versus 12/48, p=0.01).  Regardless of site, the 
TrkA positive group had a lower proportion of well differentiated and a higher proportion 
of moderately differentiated SCCs compared to the TrKA negative group (65% and 35% 
versus 92% and 8% respectively, p=0.0006).  A significantly greater proportion of TrkA 
positive cases were high-risk morphologic variants (12/40, 30% TrKA positive versus 
4/65, 6.2% TrKA negative; p=0.002) (Table 4, Fig. 4). TrkA was expressed in 25% of 
PNI positive cSCCs as compared to 16% of PNI negative cSCCs, although this difference 
was not significant (p=0.33).  
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Table 4.  TrkA and histopathologic prognosticators 
Variable 
TrkA Positive 
Casesa 
No.  (%)  n = 40 
TrkA Negative 
Casesa 
No.  (%)  n = 65 
p-
values 
Sex 
   Male 
   Female 
 
28   (70.0) 
12   (30.0) 
 
36   (55.4) 
29   (44.6) 
 
0.14 
Site 
   H&N 
   Non-H&N 
 
28   (70.0) 
12   (30.0) 
 
29   (44.6) 
36   (55.4) 
 
0.01* 
Depth (mm) 
   0.01-2.00 
   2.01-3.99 
   > 4.00 
 
15   (37.5) 
21   (52.5) 
4     (10.0) 
 
18   (27.7) 
40   (61.5) 
7     (10.8) 
 
0.57 
Clark Level 
   I 
   II 
   III 
   IV 
   V 
 
0     (0.0) 
0     (0.0) 
8     (20.0) 
32   (80.0) 
0     (0.0) 
  
0      (0.0) 
0      (0.0) 
11   (16.9) 
54   (83.1)  
0     (0.0) 
 
0.79 
Differentiation 
   Well differentiated 
   Moderately differentiated  
   Poorly differentiated 
 
26  (65.0) 
14  (35.0) 
0    (0.0) 
 
60   (92.3) 
5     (7.7) 
0     (0.0) 
 
0.0006* 
High-risk morphologic 
Variantb 
   Yes 
   No 
 
12  (30.0) 
28  (70.0) 
 
4    (6.2) 
61  (93.9)  
 
0.002* 
Perineural Invasion 
  Present 
  Absent 
 
10  (25.0) 
30  (75.0) 
 
 
11  (16.9) 
54  (83.1) 
 
 
0.33 
* Unadjusted p-values were calculated using chi-squared test of independence or Fisher’s test 
when expected frequencies were less than 5; unadjusted p-values were considered significant 
when <.05  
aTrkA data was unavailable for 5 cases due to tissue loss during antigen retrieval.  
bHigh-risk morphologic variants include acantholytic, desmoplastic, or spindle cell subtypes 
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Figure 4: Representative examples of immunohistochemical staining with TrkA in 
high-risk morphologic SCC variants 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
a  SCC, acantholytic/pseudoglandular variant, case 98  
b. SCC, desmoplastic variant, case 99 
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Desmoplastic Melanoma – Materials and Methods 
 
4.1 Sample Selection 
              This study was approved by the institutional review board of Boston University 
School of Medicine (IRB Docket #s H-32816, H-32952). Archival annotated tissue 
samples with a diagnosis of DM (n=43) were retrieved from the pathology files of the 
Skin Pathology Laboratory, Boston University School of Medicine, Boston, MA, USA. 
Inclusion criteria were randomly selected cases of primary melanoma with adequate 
tumoral tissue to allow for analyses. Histologic sections of all cases were reviewed by 
two board-certified dermatopathologists (initial sign-out on all by a dermatopathologist; 
cases were then re-reviewed, and the diagnoses confirmed). All patient data were de-
identified. 
 
4.2 Immunohistochemical Analyses of TrkA Expression 
                Formalin-fixed, paraffin-embedded tissue of  primary melanomas (n=43)  were 
baked at 75°C for 30 min. Sections were deparaffinized with xylene and rehydrated in a 
series of decreasing concentrations of ethanol solution. Heat-induced antigen retrieval 
was carried out in Dako retrieval solution (Dako, Carpenteria, CA, USA) with a Ph of 6.1 
in a 98°C bath for 20 minutes. All immunostained slides were reviewed in a blinded 
fashion. The slides were treated with dual endogenous enzyme block (Dako) then 
incubated with anti-TrkA (14G6) rabbit monoclonal antibody (Cell Signaling 
Technology, Danvers, MA, USA) at a dilution of 1:200 for 50 minutes at room 
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temperature, followed by treatment with polymer HRP (DAKO) for 20 minutes. Color 
development and contrast were achieved using DAB and hematoxylin respectively.  
 Positive TrkA expression was defined as either membranous or mixed 
membranous/cytoplasmic staining observed in tumor cells, those displaying only 
cytoplasmic staining were considered negative Membranous staining of basal epidermal 
cells, eccrine epithelial cells, mature sebocytes, and the outer root sheath of hair follicles 
served as positive internal controls where they could be visualized. 
 
4.3 Analysis of p75NGFR expression and RET Polymorphism  
Sections from the same formalin-fixed paraffin-embedded tissue blocks of DM 
cases used in the present study were analyzed previously for p75NGFR expression and 
RET G619S polymorphism.74 Briefly, p75NGFR expression was determined via IHC 
analysis using an anti-p75NGFR antibody (1:100 Biocare Medical, LLC, Concord, CA, 
USA), slides were scored using cut-offs based on the methodology reported by Iwamoto 
et al.,17 for statistical purposes cases with 11% or more of tumor cells staining were 
considered positive. RET polymorphisms were detected by direct DNA sequencing in the 
RET coding region on exon 11 with the forwarding primer, more detailed methodology 
can be found in Miller et al (2012).  
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4.4 Statistical Analyses 
 The associations between PNI and p75NGFR with potential confounding factors 
were separately assessed using univariate analysis. A chi-squared test of independence 
was utilized for categorical demographics (gender) and the following histopathologic 
prognosticators: Breslow’s depth;  Clark’s Level; pure vs mixed subtype; host response; 
ulceration; and regression. Fisher’s exact test was used if the expected frequencies were 
less than 5, and a student’s t-test was used to examine the association of age with PNI and 
p75NGFR.   Factors associated with both PNI and p75NGFR, but not believed to be on 
the causal pathway, were controlled for in a multivariable logistic regression model.  
Although underpowered, additional logistic models were examined utilizing factors 
associated with either PNI or p75NGFR (but not both), as well as a stratified analysis of 
mixed versus pure type DM. All statistical tests were done using SAS® 9.3. 
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DESMOPLASTIC MELANOMA – RESULTS 
 
5.1 Clinical Data 
 Of the 43 cases of DM studied, 24 were male and 19 were female. The median 
age at the time of diagnosis was 72 years (range: 16–92), and tumors presented in 
predominantly sun-exposed sites. A total of 21 of 43 were located on the head and neck, 
14 of 43 on the extremities, and 7 of 43 on the trunk.  Clinically apparent pigmentation 
was reported in 18 of 41 cases (data not available for two cases).   
 
5.2 PNI in DM 
 PNI was observed in 29/43 (67%) of cases of DM. Of histopathologic variables 
analyzed, both greater Clark’s Level and increased Breslow’s depth were significantly 
associated with PNI (p=0.002 and p=0.01 respectively). Notably, 31% of PNI-positive 
cases exhibited Clark’s Level V invasion compared to 7% of PNI negative cases.  
Presence of mitosis, host response, ulceration, and regression were not significantly 
associated with PNI.  No difference was noted in the propensity of the pure and mixed 
variants of DM for PNI (Table 5). 
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Table 5. PNI and Histopathologic Variables in Desmoplastic Melanoma 
Variable 
PNI Positive Cases, No. 
(%) n=29 
PNI negative cases, No. 
(%) n=14 
p-
values* 
Sex 
   Male  
   Female 
 
16   (57.1) 
12   (42.9) 
 
8   (57.1) 
6   (35.3) 
 
0.68 
Breslow’s Depth 
(mm) 
   0.01-1.00 
   1.01-2.00 
   2.01-4.00 
   > 4.00 
 
2     (6.9) 
6     (20.7) 
14   (48.3) 
7     (24.1)  
 
7    (50.0) 
3    (21.4) 
3    (21.4) 
1    (7.1) 
 
 
0.01 
Clark’s Level 
   I 
   II 
   III 
   IV 
   V 
 
0      (0.0) 
0      (0.0) 
0      (0.0) 
20   (69.0) 
9     (31.0) 
 
99 (0.0) 
99 (0.0) 
5    (35.7) 
8    (57.1) 
1    (7.1) 
 
 
0.002 
Desmoplastic 
Variant# 
   Pure 
   Mixed 
 
15  (51.7) 
14  (48.3) 
 
9    (64.3) 
5    (35.7) 
 
0.44 
Mitosis 
   Present 
   Absent 
 
26   (89.7) 
3     (10.3) 
 
10  (71.4) 
4    (28.6)  
 
0.19 
Host Response 
   Present 
   Absent 
 
13    (44.8) 
16    (55.2) 
 
4    (28.6) 
10  (71.4)  
 
0.34 
Ulceration 
   Present 
   Absent 
 
2      (6.9) 
27    (93.1) 
 
1     (7.1) 
13  (92.9) 
 
1.00** 
Regression 
   Present 
   Absent 
 
1      (3.4) 
28    (96.6) 
 
2     (14.3) 
12   (85.7) 
 
0.24 
*: Unadjusted p-values were calculated using chi-squared test of independence or 
Fisher’s test when expected frequencies were less than 5; unadjusted p-values were 
considered significant when <.05  
**: There was insufficient power to resolve an approximate p-value using Fisher method. 
#: Tumors were classified as mixed desmoplastic melanoma per previously established 
criteria24 if two morphologically distinct cell populations were present; with at least 10% 
of cells representing conventional melanoma. Pure desmoplastic melanomas were defined 
as those with >90% of cells displaying typical desmoplastic melanoma morphology.  
Note: 1 case missing gender data, 1 case missing age data 
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5.3 TrkA in DM 
 
 TrkA expression was negative in all cases of DM. Negative expression was 
confirmed by validation of positive staining of internal controls (Figure 5D-F). 
 
5.4 RETp in DM 
  Functional RET polymorphism (RETp) was detected in 12/42 (29%) of DMs 
(one case, 42, had insufficient tissue for analysis). While a greater percentage of PNI 
positive cases exhibited RETp (39% in PNI positive versus 13% in PNI negative cases) 
this difference was not significant on univariate analysis (p=0.27). RETp was not 
associated with any histopathologic variables on univariate analysis (Table 6).  
Multivariate analysis controlling for the presence of p75NGFR expression did not show a 
significant association with PNI. 
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Table 6.  RET Polymorphism and Histopathologic Variables 
Variable 
RET Polymorphism 
No. (%) n = 12 
RET Wild-Type 
No. (%) n = 30 p-values* 
Sex 
   Male 
   Female 
 
9    (75.0) 
3    (25.0) 
 
14    (48.3) 
15    (51.7)  
 
0.17 
Depth (mm) 
   0.01-1.00 
   1.01-2.00 
   2.01-4.00 
   > 4.00 
1     (8.3) 
4     (33.3) 
3     (25.0) 
4     (33.3)  
 
8       (26.7) 
5       (16.7) 
13     (43.3) 
4       (13.3) 
 
0.20 
Clark Level 
   I 
   II 
   III 
   IV 
   V 
 
0      (0.0) 
0      (0.0) 
1      (8.3) 
8     (66.7) 
2     (25.0) 
 
0       (0.0) 
0       (0.0) 
4       (13.3) 
19     (63.3) 
7       (23.3) 
 
1.00** 
Desmoplastic Variant 
   Pure 
   Mixed 
 
7     (58.3) 
5     (41.7) 
 
16   (53.3) 
14   (46.7) 
 
0.77 
Mitosis 
   Present 
   Absent 
 
8    (66.7) 
4    (33.3) 
 
27    (90.0) 
3      (10.0)  
 
0.09 
Host Response  
  Present  
  Absent 
 
6    (50.0) 
6    (50.0) 
 
11      (36.7) 
19      (63.3) 
 
0.43 
Ulceration 
  Present 
  Absent 
 
2     (8.3) 
10   (91.7) 
 
2     (6.7) 
28   (93.3) 
 
1.00** 
Regression 
  Present 
  Absent 
 
1     (8.3) 
11  (91.7) 
 
2    (6.7) 
28  (93.3) 
 
1.00** 
Note: 1 case missing gender data, 1 case missing age data. 
*: Unadjusted p-values were calculated using chi-squared test of independence or 
Fisher’s test when expected frequencies were less than 5; unadjusted p-values were 
considered significant when <.05  
**: There was insufficient power to resolve an approximate p-value using Fisher method. 
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5.5 p75NGFR in DM 
 Overall, p75NGFR expression was detected in 28/43 (65%) of DMs (17 with 10% 
or less staining, 1 with 11-50% staining, 7 with 51-75% staining and 20 with >75% 
staining of cells). Staining intensity was uniformly strong wherever present. On 
univariate statistical analysis,  p75NGFR expression was significantly associated with 
increasing Breslow’s depth and greater Clark’s Level (p=0.007 and p=0.01 respectively, 
Table 7). P75NGFR was significantly associated with PNI (Table 8), with expression 
noted in 79% of PNI positive cases and 36% of PNI negative cases (p=0.005).   
 After examining potential confounders using univariate analysis, only depth was 
associated with both PNI and p75NGFR. Although both Breslow’s Depth and Clark’s 
Level provided information on the associations of depth with PNI and p75NGFR, we 
chose to dichotomize the depth as <2mm and ≥2mm to increase statistical power in the 
multivariable logistic model.  Adjusting for the potential confounding effects of depth, 
we observed that expression of p75NGFR was associated with a 386% increase in odds 
of PNI (Adjusted Odds Ratio=4.68, 95% CI: 1.03-21.17, p=0.04). Additional 
multivariable logistic models were then created using histopathologic factors that were 
marginally associated with PNI or p75NGFR.  After step-wise inclusion of additional 
confounding factors in the multivariate analyses, the magnitude of the association 
between PNI and p75NGFR, as measured by the odds-ratio, remained relatively stable 
(Table 9).  Although not reaching the 0.05 significance level, the pure variant showed a 
greater association between PNI and p75NGFR (OR=6.57, 95%CI: 0.84–51.04, p=0.07) 
compared to mixed DM (OR=4.50, 95%CI: 0.25–80.56, p=0.31). 
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Table 7.  p75NGFR Expression and Histopathologic Variables  
Variable 
p75NGFR positive cases 
No. (%) n = 28 
p75NGFR negative 
cases No. (%) n = 15 p-values* 
Sex 
   Male 
   Female 
 
55    (55.6) 
12    (44.4) 
 
9    (60.0) 
6    (40.0)  
 
0.78 
Depth (mm) 
   0.01-1.00 
   1.01-2.00 
   2.01-4.00 
   > 4.00 
 
2      (7.1) 
6      (21.4) 
12    (42.9) 
8      (28.6)  
 
7      (46.7) 
3      (20.0) 
5      (33.3) 
0      (0.0) 
 
0.007 
Clark’s Level 
   I 
   II 
   III 
   IV 
   V 
 
0      (0.0) 
0      (0.0) 
2      (7.1) 
16    (57.1)  
10   (35.7) 
 
0      (0.0) 
0      (0.0) 
3      (20.0) 
12    (80.0) 
0       (0.0) 
 
0.01 
Desmoplastic 
Variant 
   Pure 
   Mixed 
 
15   (53.6) 
13   (46.4) 
 
9      (60.0) 
6      (40.0) 
 
0.69 
Mitosis 
   Present 
   Absent 
 
25   (89.3) 
3     (10.7) 
 
11    (73.3) 
4      (26.7)  
 
0.22 
Host Response  
  Present  
  Absent 
 
12   (42.9) 
16   (57.1) 
 
5     (33.3) 
10   (66.7) 
 
0.54 
Ulceration 
  Present 
  Absent 
 
2     (7.1) 
26   (92.9) 
 
1     (6.7) 
14   (93.3) 
 
1.00** 
Regression 
  Present 
  Absent 
 
2    (7.1) 
26  (92.9) 
 
1     (6.7) 
14   (93.3) 
 
1.00** 
*: Unadjusted p-values were calculated using chi-squared test of independence or 
Fisher’s test when expected frequencies were less than 5; unadjusted p-values were 
considered significant when <.05  
**: There was insufficient power to resolve an approximate p-value using Fisher method.  
Note: 1 case missing gender, 1 case missing age data. 
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Table 8.  Neurotrophin Receptors and Perineural Invasion in Desmoplastic 
Melanoma – Univariate analysis 
 
 Positive for TrkA 
Expression 
No. (%) 
Positive for 
p75NGFR 
Expression 
No. (%) 
Positive for RET 
polymorphism# 
No. (%) 
PNI Positive Cases  
n=29 
 
 
0  (0.0) 
 
23  (79.3) 
 
10  (38.5) 
PNI Negative 
Cases  
n=14 
 
0  (0.0) 
 
5   (35.7) 
 
2    (12.5) 
 
p-values* 
 
 
1.00 
 
 
0.005 
 
0.27 
*: Unadjusted p-values were calculated using chi-squared test of independence or 
Fisher’s test when expected frequencies were less than 5; unadjusted p-values were 
considered significant when <.05 
 #: One case was not analyzed for RET polymorphism (Case #42). 
 
 
Table 9. Multivariate Analysis of p75NGFR Expression and Propensity for PNI 
Controlling for Potential Confounding Variables.   
Model OR# 95% CI p-values 
p75NGFR + depth 4.68 1.03-21.17 0.04 
p75NGFR + depth + host response 4.26 0.90-20.09 0.07 
p75NGFR + depth +mitosis 4.26 0.92-19.78 0.06 
P75NGFR + depth + host response 
+ mitosis 
3.74 0.76-18.42 0.10 
#: odds ratio for PNI in p75NGFR positive vs p75NGFR negative cases, controlling for 
the other factors in the model.  
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Figure 5. Desmoplastic melanoma, representative examples of neurotrophin 
receptors analyzed in current study  
(A)PNI, H&E 20X (B) Corresponding section demonstrating PNI with p75NGFR 
immunohistochemicial staining, 20x  (C) GGT/AGT functional RET polymorphism 
(RETp) at codon 691 of exon 11 (D – F) Immunohistochemical staining with TrkA 
demonstrating positive staining of only internal controls. (D) Positive staining of basal 
epidermal keratinocytes, negative staining of atypical lentiginous melanocytic 
proliferation, 20X, (I )Positive staining of eccrine glands, negative staining of adjacent 
DM cells, 40X, (F) Positive staining of follicular keratinocytes, negative staining of 
atypical lentiginous melanocytic proliferation extending along follicular epithelium, 
20X. 
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DISCUSION 
In this study PNI was investigated in both cSCC and DM, two cutaneous 
malignancies with a known propensity for PNI. Further, the expression of TrkA was 
investigated in both DM and cSCC while p75NGFR and RETp were additionally 
investigated in DM.  
As mentioned previously, select studies have shown that cSCCs located on the on 
the H&N have a higher propensity for PNI.14,93–95 Findings from our study, which to the 
best of our knowledge is the first to specifically compare PNI in SCCs from the H&N 
versus non-H&N areas indicate that there may be an increased incidence of PNI in the 
former.  While differences between both groups did not achieve statistical significance, 
we observed a trend towards greater rates in the H&N comparing the incidence in H&E 
versus DIS (p=0.49 & p= 0.30 respectively).   Due to the relative rarity of PNI detection, 
larger sample sizes are required to confirm our findings 
The difficulty of detecting PNI using H&E alone has resulted in attempts to 
enhance detection with the use of immunohistochemistry in a spectrum of lineage-
unrelated cutaneous as well as non-cutaneous malignancies, with most studies detection 
[incorporating a single immunostain, typically for enhanced nerve.9,17,18,22  In cutaneous 
malignancies, immunohistochemistry has been used for PNI detection in melanoma, basal 
cell carcinoma (BCC) and cSCC.9,17,22,96 In melanomas, Scanlon et al. using antibodies to 
neurofilament found an enhanced detection of PNI (25% with H&E versus 47% with 
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immunostaining), while in SCCs from the oral mucosa Kurtz et al. using an antibody to 
S100 also found an increased incidence (62% with H&E versus 82% with 
immunostaining).9,17 In a recent study of 34 cases of cSCC, mostly from the H&N, Kelso 
et al. reported an increase in the incidence of PNI  from 18% with H&E staining to 35% 
with S100 and 38% with p75NGFR (the low-affinity nerve growth factor receptor) 
immunostaining.96   Zhou et al. concluded that DIS is superior to using a single 
imunnostaining in the identification of PNI in gastric adenocarcinoma.18 Briefly, using 
anti-S100 antbodies for nerve detection and AE1/3 antibodies to label tumor cells,  Zhou 
et al. observed  an increased incidence of PNI from 57% to 65% (comparing S100 
staining alone versus DIS) in gastric adenocarcinomas, arguing in favor of an enhanced 
sensitivity for PNI detection with DIS. Lastly in a recent study of both BCCs and SCCs 
Berlingeri-Ramos et al. compared PNI detection with S100 and AE1/3 DIS to H&E and 
reported a 33% increase in PNI detection, noting that DIS “was particularly useful to 
resolve the diagnostic dilemma of perineural proliferation and peritumormal fibrosis”.22 
We too observed a statistically significant increased detection rate of PNI with the use of 
DIS and additionally found a correlation of DIS detected PNI with tumor depth, a known 
prognosticator of high-risk cSCC, underscoring the clinical significance of using DIS as 
an adjunct in tumor microstaging. 
TrkA serves as the  membrane bound high-affinity receptor tyrosine kinase for the 
neurotrophin NGF and is known to play a role in the development and maintenance of the 
peripheral nervous system.97Additionally, TrkA expression in normal human 
keratinocytes along with NGF, has been shown to play a role in proliferation and growth 
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of keratinocytes in vitro.46 In keeping with this observation, we noted TrkA expression to 
be strongest in keratinocytes in the basal layer of the epidermis in uninvolved skin. Of 
note, this gradient appeared to be lost in epidermis over cSCC tumors with cytoplasmic 
staining typically observed pan-epidermally suggesting aberrant TrkA expression.    
Immunohistochemical studies have shown that TrkA expression correlates with 
PNI in multiple non-cutaneous malignancies, including salivary adenoid cystic 
carcinoma, oral SCC, prostate, and pancreatic cancer.50–52,98 As mentioned previously, 
Chen-Tsai et al. noted an association between TrkA expression and PNI in cSCC, albeit 
in a restricted number of samples (n=8), and with their scoring done as a subjective 
measurement of intensity rather than in a semi-quantitative manner. Furthermore, they 
did not differentiate between membranous and cytoplasmic expression. In the present 
study, TrkA positivity was restricted to cases displaying membranous staining and graded 
in a semi-quantitative manner. Using this stringent criterion, we found TrkA expression 
was not associated with PNI in cSCC, and not expressed at all in DM. The discrepancies 
between our findings and those of Chen-Tsai et al. may be explained by the use of 
different scoring systems or additionally by the fact that in their study, Chen-Tsai et al. 
used an antibody that labels the entire Trk family and not exclusively TrkA. It is possible 
that in cSCC PNI is mediated by a different Trk receptor (TrkB or TrkC) although future 
research is needed.  
For DM, in one study by Flørenes et al. using IHC to investigate expression of 
activated TrkA (p-Trka),58 positive expression was noted in 55% of primary melanomas 
(none of which were DMs or of spindled morphologies) and 30% of metastasis.  Flørenes 
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et al. also noted that membranous p-TrkA expression was associated with decreased 
overall survival, and elevated markers of proliferation (cyclin A and Ki-67). Our finding 
that TrkA was not expressed in any cases of DM, indicates that TrkA is unlikely to play a 
role in its pathogensis. Likely explanations for the discordancy between our findings and 
those of Flørenes et al. include differential TrkA expression in non-DM variants and/or, 
the use of antibodies targeting different epitopes (for example phosphorylated vs the non-
phosphorylated form of the TrKA receptor). Arguing against the former is our own 
experience using the present antibody in over 40 non-DMs which consistently 
demonstrated negative staining in all cases (data not included).   
In cSCC, despite its lack of correlation with PNI, we observed other noteworthy 
correlations between TrkA and histopathologic prognosticators. Of Note, our finding of 
more frequent TrkA expression in cSCCs from the H&N, may relate to previous findings 
that ultraviolet radiation modulates TrkA expression in human keratinocytes. Ultraviolet 
radiation is a known potent inducer of apoptosis and there is in vitro evidence to indicate 
that TrkA and NGF expression are reduced in UV-irradiated human keratinocytes in 
culture.46 In the same study, transfection of normal human keratinocytes with NGF 
resulted in resistance to UV-induced apoptosis, suggesting that shut-down of the TrkA-
NGF axis promotes apoptosis. In areas chronically sun exposed, a failure to down-
regulate TrkA expression may cause a loss of this protective apoptotic response leading 
to an increased mutational burden and tumor formation. Additionally, we found TrkA 
was more commonly expressed in high-risk morphologic variants and less well 
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differentiated cSCCs, suggesting an association between TrkA expression and changes in 
cytomorphology. 
. 
 Polymorphism in the RET gene (RETp) have been shown to be more common in 
DMs as compared to conventional melanomas,73 and in vitro studies of melanoma cell 
lines have shown that RETp results in enhanced proliferation, migration, and invasion 
upon treatment with GDNF compared to cells with wild-type RET.72  In pancreatic 
cancers RET-GDNF signaling has emerged as a potential mediator of PNI, with paracrine 
signaling between nerve and tumor cells believed to occur.63,64 Given this, we 
hypothesized that RETp would be observed in a greater proportion of PNI positive cases. 
However, we observed a non-significant 3-fold increase in the proportion of RETp 
among PNI positive samples compared to PNI negative samples (39% versus 13%). 
While not significant, our findings suggest an association between RETp and PNI, and a 
larger study may be better powered to detect a significant correlation. Additionally, for 
cases in which RETp data was available, 5 displayed PNI but were p75NGFR negative. 
Of these, 3 (60%) had RETp, suggesting that in the absence of p75NGFR expression 
RETp may be of relevance in PNI. Our observation that only 7% of PNI positive cases 
lacked both RETp and p75NGFR, as compared to 57% of PNI negative cases (p=0.0008), 
underscores the potential role played by each. 
 While expression of p75NGFR has long been associated with the spindled 
cytomorphology in melanomas, much of the previous research has focused on the utility 
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of staining for p75NGFR as an adjunct to help identify S100-negative spindle cell 
melanomas and, to differentiate spindle cell melanomas from other lineage-unrelated 
spindle cell lesions of the skin.80,82,83  Though some have demonstrated staining for 
p75NGFR in 100% of cases of DM,80,82,88 we observed positive staining in 65% of our 
cases. However, select studies have also noted variable expression of p75NGFR in DM, 
corroborating our findings.84,85 These discrepancies do not appear to be simply the result 
of variable scoring rubrics as, using similar cut-offs, studies reporting 100% of DMs 
staining for p75NGFR did not observe any cases with 10% or less tumoral staining.80,82,88 
Hence, we hypothesize that these differences may be the result of differing anti-bodies 
used and the relatively small samples sizes (<15) of previous studies.  
The fact that p75NGFR expression is found more often in DM than in other 
subtypes, when taken together with DM’s significant propensity for PNI has led some to 
hypothesize that p75NGFR may play a functional role in PNI.85,88 Our findings  show 
that beyond p75NGFR’s previously known association with this variant, it is further 
associated with PNI, even after controlling for depth. In vitro studies on melanoma cell 
lines have shown that p75NGFR mediates the induction of protease expression in 
response to NGF treatment, resulting in an enhanced invasive capacity.57 Furthermore, 
NGF has been shown to exert chemotactic effects on melanoma cell cultures, with 
p75NGFR mediating the response.99 Taken together, from a scientific perspective it is 
reasonable to hypothesize that p75NGFR is associated with a greater propensity for PNI 
by allowing for both an enhanced invasiveness in response to NGF (permitting 
proteolytic digestion of the perineurium) and a chemotactic attraction to the NGF-rich 
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microenvironment of nerve as NGF is known to be secreted by Schwann cells.47 Lastly, 
p75NGFR is a promiscuous receptor, and binds other Neurotrophins besides NGF (such 
as neurotrophin-3 and Brain-derived neurotrophic factor) each of which  may have an 
additional role to play in affecting the behavior of melanomas expressing p75NGFR. 
In conclusion, findings from this study indicate that in cSCCs, the increased 
detection of PNI using DIS and its correlation with select histopathologic prognosticators, 
underscore the utility of immunohistochemistry as an adjunct in microstaging. The 
association between TrkA expression and select adverse histopathologic parameters 
suggests a role for the NGF-TrKA axis in tumorogenesis of cSCC. Our observation that 
TrkA expression is significantly more common in cSCCs of the H&N than in non-H&N 
areas is indicative of the heterogeneity amongst SCCs from different anatomic sites. 
TrkA expression in cSCCs alone and not in DMs indicates that expression may be 
lineage-related.  Expression of p75NGFR in DMs was associated with a greater 
propensity for PNI. While we did not observe a significant correlation between RETp and 
PNI, the 3 fold increase in RETp incidence observed in samples displaying PNI suggests 
that a larger study may be better powered to detect an association. Lastly, our 
observations in cases of DM with PNI that only a limited number (7%) were negative for 
both RETp and p75NGFR highlights the potential role played by each. 
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